Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bone Healing Accelerant Versus Standard of Care for Open Tibia Fractures

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03826784
Recruitment Status : Withdrawn (Combined into an international study (CAR-BHA-I21))
First Posted : February 1, 2019
Last Update Posted : January 23, 2020
Sponsor:
Information provided by (Responsible Party):
Carmell Therapeutics Corporation

Brief Summary:
This clinical study is being conducted to demonstrate the safety and effectiveness of the Bone Healing Accelerant (BHA) product when applied to tibia (leg bone) fractures with an external wound or skin break (also called open tibia fractures). It is hypothesized that by 6 months, the number of subjects with successful bone healing will be greater in the BHA-treated group compared to subjects treated with standard of care alone. Open tibia fractures were chosen for this study because healing rates are typically longer than for other bone fractures due to the limited vascular supply, limited soft tissue coverage, and higher risk of infection.

Condition or disease Intervention/treatment Phase
Tibial Fractures Combination Product: BHA Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Controlled, Blinded Study of the Efficacy and Safety of Bone Healing Accelerant Versus Standard of Care in Subjects With Open Tibia Fractures
Estimated Study Start Date : November 2019
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : February 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BHA
Subjects treated with BHA + standard of care
Combination Product: BHA
BHA active ingredients include a blood-derived component and beta-tricalcium phosphate. It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.

No Intervention: Control
Subjects treated as per standard of care



Primary Outcome Measures :
  1. Composite healing measure [ Time Frame: 6 months ]
    Proportion of subjects in each arm meeting the healing success criteria. A binary (Yes/No) outcome for overall healing will be derived from the following three outcomes: Radiographic healing as measured by a score of at least 13 on the modified Radiographic Union Scale in Tibia fractures (mRUST, range bad to good 1-16), ambulation as measured by a score of at least 2 on the Function IndeX for Trauma scale (range bad to good 0-3), and no secondary intervention to promote bone healing. All three components must be met for a "yes" on composite healing.


Secondary Outcome Measures :
  1. Radiographic healing [ Time Frame: 6 months ]
    Population mean Modified Radiographic Union Scale in Tibia Fractures (mRUST) scores (range bad to good is 4-16)

  2. Secondary intervention (surgical or nonsurgical) [ Time Frame: 6 months ]
    Proportion of subjects not having secondary intervention conducted specifically to promote bone healing needed

  3. Surgical site infection [ Time Frame: 12 months ]
    Proportion of subjects having surgical site infection through 12 months as determined by CDC guidelines



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

In order to be eligible to participate in this study, subjects must meet all of the following criteria:

  1. Patient is between the ages of 18-75 inclusive at time of randomization.
  2. Patient has an acute open Gustilo-Anderson Type IIIA or IIIB fracture of the tibia shaft, with or without a fibula fracture, secondary to trauma.
  3. Patient received antibiotic treatment within 2 hours of presentation at initial medical facility.
  4. Patient underwent their first operative debridement within 24 hours of presentation at initial medical facility.
  5. Patient is scheduled to have DWC within 14 days of initial injury.
  6. The tibia fracture requires open fracture reduction and internal fixation with intramedullary (IM) nailing;

    • IM nailing has been cross-locked for stability with a 4-5mm interlock, with a minimum of 1 static screw above the fracture site and 1 static screw below the fracture site, and
    • All IM nails have a diameter between 8.5-12mm with 1.0-1.5mm over-reaming of the canal.

    The temporary use of external fixation prior to IM rodding and DWC is allowed.

  7. Upon stabilization of the tibia fracture, the patient has a cortical deficit of less than or equal to 1.0cm involving no more than 50% of the tibia circumference. The cortical deficit of the residual 50% circumference must be less than 1.0cm. Gap assessments to be made with calibrated radiographs or visual inspection. In addition, patients are not likely to require a secondary procedure(s) to promote bone healing.
  8. BHA is able to be applied through existing soft tissue defects created by the injury or those created during surgical treatment. No new incisions should be required specifically for application of BHA.
  9. Patient is willing and able to comply with all study procedures including all pre-operative, post-operative and rehabilitation requirements.
  10. Patient is able to give voluntary IC to participate and has signed an IC form specific to this study prior to study treatment and DWC.
  11. Patients of childbearing potential must use adequate methods of contraception during the duration of follow-up (12-months). Adequate methods include abstinence, female and male sterilization, hormonal contraceptives, intrauterine devices (IUDs), implants, injectables, and double barrier methods.

Exclusion Criteria:

  1. Patients who are currently participating in another investigational trial or having participated in a clinical investigation within the last 90 days or intend to during the course of the study.
  2. Patients who are currently prisoners.
  3. Patients who are unable to give informed consent.
  4. Patients who are skeletally immature (<18 years of age or radiographic evidence of open tibial physes).
  5. Patients with Type I, II, or IIIC open tibia fractures according to the Gustilo-Anderson classification.
  6. Current injury is a pathological fracture.
  7. Patients with additional injuries that could impact their ability to complete the required assessments and postoperative rehabilitation. Examples include but are not limited to the following:

    1. Head injury with impaired cognitive function,
    2. Spinal injury with resultant neurologic weakness or paralysis,
    3. Multi-trauma requiring prolonged hospitalization or recovery that, in the opinion of the investigator, the treatment and/or rehabilitation of such injuries will substantially interfere with the treatment, rehabilitation or other requirements outlined in this protocol,
    4. Concomitant ipsilateral or contralateral lower extremity injury/fracture(s) if, in the opinion of the investigator, the treatment and/or rehabilitation of such fracture(s) will substantially interfere with the treatment, rehabilitation or other requirements outlined in this protocol.
    5. Sustained severe burns (>10% total body surface area [TBSA] or >5% TBSA with full thickness or circumferential injury)
    6. Compartment syndrome of the leg diagnosed preoperatively
  8. Patients with pre-existing conditions, mental/psychosocial disorders, or who are taking medication that may delay or impair the fracture healing process or that could impact their ability to return for follow-up visits and/or complete the required assessments and postoperative rehabilitation. Examples include but are not limited to the following:

    1. Renal insufficiency with serum creatinine of 3.5 mg/dL or higher or being treated with renal dialysis,
    2. Uncontrolled diabetes mellitus with A1C of greater than or equal to 10%,
    3. Serum Aspartate Aminotransferase (AST) greater than 2 times the upper limit of normal or diagnosed hepatitis C or hepatitis B,
    4. Neurological or neuromuscular disorders affecting ambulatory capability or cognition, such as Parkinson's disease, myasthenia gravis, or stroke with relevant residual neurological deficit,
    5. Current medications that could interfere with fracture healing such as systemic corticosteroids,
    6. Morbid Obesity with BMI greater than or equal to 40 kg/m2,
    7. A current endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, hyperthyroidism, parathyroid hormone disorder, Ehler-Danlos syndrome, osteogenesis imperfecta, or Cushing's disease),
    8. History of osteomyelitis of index lower extremity or evidence of active soft tissue or bone infection at this site of injury at the time of DWC,
    9. Patients with immune deficiency or history of auto-immune disease.
  9. Patients with an active malignancy or a history of any invasive malignancy (except non-melanoma skin cancer), unless the patient has been treated with curative intent and there have been no clinical signs or symptoms of malignancy for at least 5 years.
  10. Patients with any medical condition or life circumstances that in the surgeon's opinion could impact their ability to return for follow-up visits and/or complete the required assessments and postoperative rehabilitation. Examples include but are not limited to the following:

    1. Patient lives too far away making the return for study visits to the surgeon's facility unlikely,
    2. The patient has known alcohol or drug abuse within 3 months of screening to a degree that makes it unlikely the patient will follow study requirements.
  11. Patients who are known to have anaphylactic or severe systemic reaction to human blood products, genipin, β-TCP, glycerin or to other components of the investigative product formulation.
  12. Female patients of child-bearing potential who meet any of the following criteria:

    • Patient is currently pregnant (prior diagnosis or a positive pregnancy test at baseline), or planning to become pregnant any time during the course of the study
    • Currently breastfeeding or planning to breastfeed at any time during the course of the study
  13. Upon stabilization of the tibia fracture, the patient has a bone gap greater than 1.0cm apparent by calibrated radiographs or by visual inspection and/or the patient is highly likely to require secondary intervention procedure(s), surgical or nonsurgical (e.g., bone stimulation or ultrasound treatment) for the index fracture.
  14. Patients who have mal-alignment post-IM nailing of >10° in the coronal plane or >15° in the sagittal plane.
  15. Patients who received only plates and screws for tibia fracture stabilization.
  16. At the time of the DWC surgery, patients who have a planned secondary intervention procedure, surgical or nonsurgical (e.g., bone stimulation or ultrasound treatment) for the index fracture.
  17. Patients being treated with any form of local antibiotics at the time of DWC.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03826784


Locations
Layout table for location information
United States, Pennsylvania
Carmell Therapeutics
Pittsburgh, Pennsylvania, United States, 15203
Sponsors and Collaborators
Carmell Therapeutics Corporation
Investigators
Layout table for investigator information
Study Director: Janet M Vargo, PhD Carmell Therapeutics
Layout table for additonal information
Responsible Party: Carmell Therapeutics Corporation
ClinicalTrials.gov Identifier: NCT03826784    
Other Study ID Numbers: CAR-BHA-U31
First Posted: February 1, 2019    Key Record Dates
Last Update Posted: January 23, 2020
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Fractures, Bone
Tibial Fractures
Wounds and Injuries
Leg Injuries